CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Percutaneous Support Devices for Percutaneous Coronary Intervention Select Drug-Drug Interactions With Direct Oral Anticoagulants Considerations for Single-Measurement Risk-Stratification Strategies for Myocardial Infarction Using Cardiac Troponin Assays Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Clinical Trial2020 Nov 11.

JOURNAL:Circulation. Article Link

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al. Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF